© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Complera

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Taking Harvoni With Viread Appears Safe for the Kidneys

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

Edurant Offers Many Benefits Over Sustiva as First-Line HIV Treatment

In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.

HIV Treatment Linked to Faster Kidney Function Decline Among Men

That’s compared with HIV-negative men.
Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

In the HIV Population, Bone Loss Is Greater Among Women

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

While Rare, Acute Kidney Injury Can Occur on Viread and Norvir

People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.

Gilead Raises Prices of HIV Meds Twice in Six Months

Increases may be designed to push patients to the company’s newer regimens.

Complera

Thinkstock

Viread (Tenofovir, TDF) Linked With Liver Disease and Cancer

Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.

Individual HIV Meds Are Just as Effective as Combo Pills

Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.

I take an older single tablet regimen, but I’m thinking about switching to a newer single tablet option. What should I consider?

We now have four single tablet regimens.

96% Hep C Cure Rate for Harvoni in Those Coinfected With HIV

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.

I take tenofovir as part of my HIV treatment. What should I know about a new kind of tenofovir being developed?

It is more easily absorbed into white blood cells meaning you can take a lower dose.

Janssen and Gilead Amend Single-Pill HIV Regimen Collaborations

Janssen and Gilead Sciences have announced amendments to ongoing collaborations to develop single-tablet regimens to treat HIV.

It’s Time for Tenofovir 2.0

One of the most important drugs in the HIV arsenal is getting a tune-up.
Advertisement